• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Qnovia Secures $17M to Advance Inhalable Therapeutics Pipeline

by Jasmine Pennic 09/28/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Qnovia Secures $17M to Advance Inhalable Therapeutics Pipeline

What You Should Know:

– Qnovia (formerly Respira Technologies)—a pharma company developing inhaled therapeutics with an initial focus on nicotine replacement therapy (NRT) and cardiopulmonary diseases—has raised $17M in Series A funding led by Blue Ledge Capital and included DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures.

– Qnovia will use the Series A proceeds to advance its NRT drug candidate through an IND submission with the FDA and begin human clinical trials in 2023.

Prescription NRT

Qnovia is tackling the world’s leading cause of preventable death and disease by helping the world’s one billion smokers successfully quit. The company is currently engaged with FDA CDER to pursue a combination product authorization as the first inhalable prescription smoking cessation therapy. RespiRx,  Qnovia’s™ combination drug product is designed to be the first inhalable prescription NRT (Nicotine Replacement Therapy) for smokers trying to quit smoking.

The RespiRx™ is an easy to use, zero-maintenance cartridge-based medical grade inhaled drug delivery system that will be prescribed by a doctor to help smokers finally quit smoking. Each cartridge is filled aseptically and contains both our proprietary aerosol generating technology and the drug product.

“This Series A closing represents a major milestone for Qnovia as we seek to develop an initial proof of concept for our platform in NRT before expanding into additional therapeutic indications,” said Brian Quigley, CEO of Qnovia. “Once the FDA approves our Investigational New Drug (IND) application, we plan to initiate a Phase 1 study for NRT in 2023. As we pursue NRT authorization, we aim to identify significant expansion indications to pursue both alone and with partnerships.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Clinical Trials, FDA, Partners, Pharma, Smoking Cessation

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

How AI Helps Health Systems Improve the Quality of Care for Patients with Chronic Conditions

How AI Helps Health Systems Improve the Quality of Care for Patients with Chronic Conditions

10 Critical KPIs Every Successful Healthcare Organization is Implementing10 Critical KPIs Every Successful Healthcare Organization is Implementing

Trending

Why The Evolution of Tech Will be Based on APIs

Why The Evolution of Tech Will be Based on APIs

Podimetrics CMO Talks Supporting Patients Living with SDoH Challenges

Podimetrics Director Talks Supporting Patients Living with SDoH Challenges

: Does Alzheimer’s Cure Matter if We Don't Fix the Economic Infrastructure of the Disease?

Does Alzheimer’s Cure Matter if We Don’t Fix the Economic Infrastructure of the Disease?

Recent Digital Health Partnerships

Roundups: 15 Recent Digital Health Strategic Partnerships

Recent Digital Health Executive Hires & Board Appointments

Digital Health Executive Hires: Practice Better Appoints CEO, HHAeXchange, Intelerad, Tegria, Others

M&A: Florence Acquires Virtual Care Solution Zipnosis

M&A: Florence Acquires Virtual Care Solution Zipnosis

Adopting Value-Based Care Models for Autism Care Is Imperative

Why Adopting Value-Based Care Models for Autism Care Is Imperative

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

Vanderbilt University Medical Center Taps Philips Reduce Carbon Footprint

Vanderbilt University Medical Center Taps Philips to Reduce Carbon Footprint

Denials Management Named Most Time-Consuming Task in RCM

Denials Management Named Most Time-Consuming Task in RCM

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |